Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Jazz Pharmaceuticals PLC to similar companies based on the strength of its profitability, earnings, valuation, dividends, institutional ownership, risk and analyst recommendations.

Volatility and Risk

Jazz Pharmaceuticals PLC has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals PLC’s rivals have a beta of 1.13, meaning that their average share price is 13% more volatile than the S&P 500.

Valuation and Earnings

This table compares Jazz Pharmaceuticals PLC and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Jazz Pharmaceuticals PLC $1.54 billion $758.97 million 22.26
Jazz Pharmaceuticals PLC Competitors $224.52 million $58.08 million -1.09

Jazz Pharmaceuticals PLC has higher revenue and earnings than its rivals. Jazz Pharmaceuticals PLC is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


This table compares Jazz Pharmaceuticals PLC and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals PLC 25.69% 22.75% 9.14%
Jazz Pharmaceuticals PLC Competitors -912.91% -186.15% -28.31%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Jazz Pharmaceuticals PLC and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals PLC 0 5 15 0 2.75
Jazz Pharmaceuticals PLC Competitors 122 462 1154 11 2.60

Jazz Pharmaceuticals PLC currently has a consensus target price of $181.20, indicating a potential upside of 26.21%. As a group, “Biotechnology” companies have a potential upside of 110.17%. Given Jazz Pharmaceuticals PLC’s rivals higher possible upside, analysts plainly believe Jazz Pharmaceuticals PLC has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

88.3% of Jazz Pharmaceuticals PLC shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 4.3% of Jazz Pharmaceuticals PLC shares are owned by insiders. Comparatively, 18.5% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Jazz Pharmaceuticals PLC beats its rivals on 9 of the 13 factors compared.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.